165 related articles for article (PubMed ID: 24871550)
21. Polymorphic and Quantum Chemistry Characterization of Candesartan Cilexetil: Importance for the Correct Drug Classification According to Biopharmaceutics Classification System.
de Campos DP; Silva-Barcellos NM; Lima RR; Savedra RML; Siqueira MF; Yoshida MI; da Nova Mussel W; de Souza J
AAPS PharmSciTech; 2018 Oct; 19(7):3019-3028. PubMed ID: 30062540
[TBL] [Abstract][Full Text] [Related]
22. Host-Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism.
Ntountaniotis D; Andreadelis I; Kellici TF; Karageorgos V; Leonis G; Christodoulou E; Kiriakidi S; Becker-Baldus J; Stylos EK; Chatziathanasiadou MV; Chatzigiannis CM; Damalas DE; Aksoydan B; Javornik U; Valsami G; Glaubitz C; Durdagi S; Thomaidis NS; Kolocouris A; Plavec J; Tzakos AG; Liapakis G; Mavromoustakos T
Mol Pharm; 2019 Mar; 16(3):1255-1271. PubMed ID: 30681344
[TBL] [Abstract][Full Text] [Related]
23. Choice of excipients for gelly-like pulp prepared ex tempore "on a spoon"- "placebo" and with sartans.
Wolska E; Kluk A; Zarazińska M; Boniecka M; Sznitowska M
Drug Dev Ind Pharm; 2016; 42(6):998-1007. PubMed ID: 26548554
[TBL] [Abstract][Full Text] [Related]
24. Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).
Bönner G; Landers B; Bramlage P
Vasc Health Risk Manag; 2011; 7():85-95. PubMed ID: 21415922
[TBL] [Abstract][Full Text] [Related]
25. A Self-Nanoemulsifying Drug Delivery System for Enhancing the Oral Bioavailability of Candesartan Cilexetil: Ex Vivo and In Vivo Evaluation.
AboulFotouh K; Allam AA; El-Badry M; El-Sayed AM
J Pharm Sci; 2019 Nov; 108(11):3599-3608. PubMed ID: 31348934
[TBL] [Abstract][Full Text] [Related]
26. LC and LC-MS/TOF studies on stress degradation behaviour of candesartan cilexetil.
Mehta S; Shah RP; Priyadarshi R; Singh S
J Pharm Biomed Anal; 2010 Jul; 52(3):345-54. PubMed ID: 19505786
[TBL] [Abstract][Full Text] [Related]
27. Understanding the interaction between Soluplus® and biorelevant media components.
Pinto JMO; Rengifo AFC; Mendes C; Leão AF; Parize AL; Stulzer HK
Colloids Surf B Biointerfaces; 2020 Mar; 187():110673. PubMed ID: 31812452
[TBL] [Abstract][Full Text] [Related]
28. Effects of angiotensin II AT1 receptor inhibition and exercise training on insulin action in rats on high-fat diet.
Wang Z; Koike T; Li P; Jiang H; Natsume Y; Mu L; Chen T; Oshida Y
Life Sci; 2012 Feb; 90(9-10):322-7. PubMed ID: 22210187
[TBL] [Abstract][Full Text] [Related]
29. Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation.
Paudel A; Ameeduzzafar ; Imam SS; Fazil M; Khan S; Hafeez A; Ahmad FJ; Ali A
Curr Drug Deliv; 2017; 14(7):1005-1015. PubMed ID: 28034361
[TBL] [Abstract][Full Text] [Related]
30. Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug.
Aly UF; Sarhan HA; Ali TFS; Sharkawy HAE
Drug Des Devel Ther; 2020; 14():1851-1865. PubMed ID: 32523332
[TBL] [Abstract][Full Text] [Related]
31. New supersaturating drug delivery system as strategy to improve apparent solubility of candesartan cilexetil in biorelevant medium.
Pinto JMO; Leão AF; Alves GF; Mendes C; França MT; Fernandes D; Stulzer HK
Pharm Dev Technol; 2020 Jan; 25(1):89-99. PubMed ID: 31583925
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers.
Jeon JY; Im YJ; Kim Y; Han SM; Jo MJ; Shin DH; Yoo JS; Moon BK; Kim BK; Lee BH; Choi YH; Cho BS; Jang HY; Chae SW; Kim MG
Drug Dev Ind Pharm; 2013 Sep; 39(9):1296-9. PubMed ID: 23030309
[TBL] [Abstract][Full Text] [Related]
33. Three dimensional macroporous hydroxyapatite/chitosan foam-supported polymer micelles for enhanced oral delivery of poorly soluble drugs.
Zhang Y; Dong K; Wang F; Wang H; Wang J; Jiang Z; Diao S
Colloids Surf B Biointerfaces; 2018 Oct; 170():497-504. PubMed ID: 29960950
[TBL] [Abstract][Full Text] [Related]
34. Preparation, characterization and
Amer AM; Allam AN; Abdallah OY
Drug Dev Ind Pharm; 2019 Jul; 45(7):1140-1148. PubMed ID: 30912678
[TBL] [Abstract][Full Text] [Related]
35. Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique.
Marasini N; Tran TH; Poudel BK; Cho HJ; Choi YK; Chi SC; Choi HG; Yong CS; Kim JO
Int J Pharm; 2013 Jan; 441(1-2):424-32. PubMed ID: 23174408
[TBL] [Abstract][Full Text] [Related]
36. The effects of surfactants on the solubility and dissolution profiles of a poorly water-soluble basic drug, carvedilol.
Incecayir T
Pharmazie; 2015 Dec; 70(12):784-90. PubMed ID: 26817275
[TBL] [Abstract][Full Text] [Related]
37. Corroboration of naringin effects on the intestinal absorption and pharmacokinetic behavior of candesartan cilexetil solid dispersions using in-situ rat models.
Surampalli G; K Nanjwade B; Patil PA
Drug Dev Ind Pharm; 2015; 41(7):1057-65. PubMed ID: 24918161
[TBL] [Abstract][Full Text] [Related]
38. Voltammetric determination of candesartan cilexetil in its Cu(II) complex and application to pharmaceutical formulations.
Süslü I; Ozaltin N; Altinöz S
J AOAC Int; 2010; 93(2):562-8. PubMed ID: 20480904
[TBL] [Abstract][Full Text] [Related]
39. Surfactant-mediated dissolution of metformin hydrochloride tablets: wetting effects versus ion pairs diffusivity.
Desai D; Wong B; Huang Y; Ye Q; Tang D; Guo H; Huang M; Timmins P
J Pharm Sci; 2014 Mar; 103(3):920-6. PubMed ID: 24549733
[TBL] [Abstract][Full Text] [Related]
40. Candesartan cilexetil effectively reduces blood pressure in hypertensive children.
Franks AM; O'Brien CE; Stowe CD; Wells TG; Gardner SF
Ann Pharmacother; 2008 Oct; 42(10):1388-95. PubMed ID: 18664605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
